title: Need for additional trials of primary prophylaxis in patients with high-risk antiphospholipid antibody profiles: comment on the article by Erkan et al.
authors.forename: Denis
authors.initials: D
authors.lastname: Wahl
authors.forename: Thomas
authors.initials: T
authors.lastname: Lecompte
authors.forename: Henri
authors.initials: H
authors.lastname: Bounameaux
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D017152:Antibodies, Antiphospholipid / Q000097:blood*; D016736:Antiphospholipid Syndrome / Q000188:drug therapy* / Q000453:epidemiology / Q000276:immunology; D001241:Aspirin / Q000627:therapeutic use*; D006801:Humans; D012307:Risk Factors; D013927:Thrombosis / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D017152:Antibodies, Antiphospholipid; D001241:Aspirin